Medigene AG announces that its US licensee, Fougera Pharmaceuticals Inc, a Sandoz company, has signed a promotion agreement with Women's Choice Pharmaceuticals LLC (WCP), a specialty pharmaceutical company based in Gilbert, Arizona, for Veregen (sinecatechins) ointment, a treatment for external genital warts. This new promotion agreement aims to expand product sales within the obstetrics, gynaecology and urology medical specialties in the United States (US).
Dr. Frank Mathias, chief executive officer of Medigene AG, comments: "We are excited that Fougera has joined forces with Women's Choice Pharmaceuticals to expand Veregen's US business into the field of obstetrics, gynaecology and urology. Fougera is now in a position to promote Veregen to all appropriate physicians for the treatment of external genital warts. We believe this is an important agreement that will help to create broader brand recognition for Veregen in the US."
In addition to the US, Veregen is also available in Canada, in 15 European countries (Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Czech Republic, Slovakia, Hungary, and Poland), and in Taiwan. The drug has obtained market approval in a number of additional countries.
Veregen (sinecatechins) is a topical ointment for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older. The product contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. Sinecatechins 10 per cent & 15 per cent Ointment (Veregen) have been included in the 2012 European Guideline for the Management of Anogenital Warts. In addition, in its 2010 Sexually Transmitted Diseases Treatment Guidelines, the US Centers for Disease Control and Prevention includes sinecatechins 15 per cent Ointment (Veregen) as an option for treating external genital warts.